Captopril converting enzyme

Bradykinin increases because the enzyme inhibited by captopril, converting enzyme, normally degrades kinins in addition to synthesizing angiotensin II (see Figure 11-4). The answer is (D). The most potent vasodilator discovered to date is calcitonin gene-related peptide. The answer is (E). 

Folic acid deficiency Hyperthermia Phenylketonuria Rheumatic disease Virilizing tumors Drugs and chemicals Androgenic chemicals Angiotensin-converting enzyme inhibitors Captopril, enalapril Antibiotics... 

Most ACE inhibitors are prodrugs, with the exceptions of captopril, lisinopril, and ceranapril. Prodrugs exert improved oral bioavailability, but need to be converted to active compounds in the liver, kidney, and/or intestinal tract. In effect, converting enzyme inhibitors have quite different kinetic profiles with regard to half time, onset and duration of action, or tissue penetration. 

Angiotensm-converting enzyme (ACE) inhibitors— for example, captopril (Capoten), enalapril (Vasotec), and lismopril (Prinivil)... 

Redshaw S. Angiotensin-converting enzyme (ACE) inhibitors and the design of captopril. In Ganellin CR, Roberts SM, editors. Medicinal chemistry. The role of organic chemistry in drug research, 2nd edition. Fondon Academic Press, 1993. p. 163-85. 

Chymostatin-sensitive Il-generating enzyme Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Trial Collaborative Study Captopril Trial ( The Effect of Angiotensin-Converting Enzyme Inhibition on Diabetic Nephropathy ) calcium channel blocking agents Candesartan in Heart Failure Assessment of Reduction in Morbidity and Mortality Trial congestive heart failure, but the latest recommendations use HF for heart failure chronic kidney disease cardiac output... 

Captopril, enalapril Angiotensin converting enzyme Hypertension... 

Figure 3.4 Interactions of (A) substrate, (B) captopril, and (C) enalaprilate with the active site of angiotensin converting enzyme.

Captopril 678 and enalapril 679 are potent angiotensin converting enzyme (ACE) inhibitors used as antihypertensives. Molecular manipulation based on the enzyme model led to the discovery of some perspective bicyclic structures, for example, cilazapril 680 and compound 681, highly active antihypertensives in vivo. Compound 681 belongs to the most potent conformationally restricted ACE inhibitors and is often used as a model for molecular modeling studies <1996JA8231>. 

The answer is b. (1 Iardman, pp 750-751) Angiotensin converting enzyme inhibitors, especially captopril, can cause alteration or loss of taste sensation... 

Peptidyl-dipeptidase A (angiotensin-I converting enzyme, ACE, EC 3.4.15.1) plays a pivotal role in the control of blood pressure [80]. It has been established that its active site contains an essential Zn-atom that functions like that of carboxypeptidase A [2], ACE is inhibited by peptides having a proline or aromatic amino acid at the C-terminal position. These observations as well as the similarities with the active site of carboxypeptidase A have allowed a rational design of effective inhibitors of ACE (e.g., captopril (3.4) and enalapril (3.5)) used in the treatment of hypertension [81]. 

Captopril (Capoten, Bristol-Myers Squibb) angiotensin converting enzyme (ACE) inhibitor for the treatment of hypertension... 

Captopril by decreasing heart rate and contraction Angiotensin converting enzyme inhibitor, decreases arterial... 

One of the hrst angiotensin converting enzyme (ACE) inhibitors was teprotide. It is an antihypertensive drug for use after heart attacks. The active ingredient was isolated from the venom of a South American viper snake. Other well-known ACE inhibitors such as captopril and analopril were developed based on modifications to the venom chemical structures. 

Bjorck JE. (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension The Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 611-616. 

Angiotensin-converting enzyme (ACE) inhibitors such as captopril exert a long-term reno-protective effect. Among other effects, they lower systemic blood pressure and renal plasma flow and effectively reduce urinary protein excretion. Renal delivery of ACE-inhibitors may increase this efficacy and reduce extra-renal side-effects. Renal targeting of an ACE-in-hibitor can also be useful in clarifying the contribution of local ACE inhibition to these reno-protective effects. 

Moreover, whether or not hypertension is caused by an elevated level of renin or other reasons, angiotensin-converting enzyme inhibitors lower both systolic and diastolic arterial pressure in hypertensive patients, and their effects are enhanced by diuretics. Angiotensin-converting drugs of this series (captopril, enalapril) are effective antihypertensive drugs used both independently and in combination with other drugs to treat all types of hypertension as well as to treat cardiac insufficiency. 

Like captopril, enalapril selectively suppresses the rennin-angiotensin-aldosterone system, inhibits angiotensin-converting enzyme, and prevents conversion of angiotensin I into angiotensin 11. 

Capoten Captopril Angiotensin l-converting enzyme (ACE) Hypertension... 

Nakagawa, K., Ueno, A., and Nishikawa, Y. (2006). Interactions between carnosine and captopril on free radical scavenging activity and angiotensin-converting enzyme activity in vitro. Yakugaku Zasshi 125, 37-42. 

---